Marker Therapeutics (MRKR) announced that Baylor College of Medicine’s TACTOPS clinical study in pancreatic cancer was featured on Good Morning America on Thursday, January 22, 2026. The segment spotlighted the Baylor-led research recently published in Nature Medicine evaluating autologous Multi-Antigen Targeted T cell therapy in patients with pancreatic ductal adenocarcinoma, PDAC, and highlighted the potential of Multi-Antigen Targeted approaches to address a significant unmet need in pancreatic cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRKR: